Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Self GRAS for stevia

This article was originally published in The Tan Sheet

Executive Summary

Blue California, a Rancho Santa Margarita, Calif.-based manufacturer, expects GRAS self-affirmation by August 2008 for high-purity rebaudioside A 99%, an isolated stevia plant compound that is 400 times sweeter than sugar, the firm says. A scientific panel completed a preliminary review of the substance and final documents are anticipated to be signed by August, the firm notes. Rebaudioside A and other stevia products are approved for use in dietary supplements in the U.S., China and certain Western European countries, but FDA has not granted GRAS status for stevia as a food product. Gilbert, Ariz.-based Wisdom Natural Brands recently launched a natural sweetener formulation derived from the stevia leaf with self-certification as GRAS (1"The Tan Sheet" June 30, 2008, p. 11). Coca-Cola and Cargill, however, are working to receive FDA's GRAS certification before they launch a rebaudioside A 99% product they developed ( 2"The Tan Sheet" May 19, 2008, In Brief)...

You may also be interested in...



Wisdom’s Unconventional Launch: Stevia Sweetener Without FDA’s GRAS

Wisdom Natural Brands launches a natural sweetener formulation derived from the stevia leaf without FDA affirming the ingredient as safe, an approach industry stakeholders say is best for the firm's business

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Topics

UsernamePublicRestriction

Register

PS101854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel